Voyager Therapeutics is trading 5.2% down at $3.26 as risk-off sentiment hits the biotech sector, extending a multi-session slide from recent highs.
- The move occurs without fresh company-specific news, suggesting traders are reacting to technical weakness and broader sector volatility rather than new developments.
- Recent market coverage has highlighted a challenging period for the firm, including ongoing cash burn concerns and the stock reaching a 52-week low.